For the millions of Americans with treatment-resistant depression or PTSD who have tried multiple medications and therapies without lasting relief, the prospect of a federally approved psychedelic treatment — once unthinkable in mainstream medicine — is now closer than at any point in modern regulatory history.
On April 24, 2026, the U.S. Food and Drug Administration issued National Priority Vouchers to three companies developing psychedelic-based therapies: Compass Pathways for its synthetic psilocybin (COMP360) for treatment-resistant depression; the Usona Institute for psilocybin for major depressive disorder; and Transcend Therapeutics for methylone (TSND-201, an MDMA-like compound) for PTSD. These vouchers were issued under the FDA Commissioner's National Priority Voucher pilot program — a mechanism that compresses the standard 10-to-12-month drug application review down to one to two months.
The action came just six days after President Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate the research, review, and approval of psychedelic drugs as treatments for serious mental health conditions.
The Three Treatments — and Where Each Stands
Compass Pathways' COMP360 (psilocybin, treatment-resistant depression): This is the most advanced of the three. Compass Pathways — a UK-based biotech company — achieved positive results in two consecutive Phase 3 trials: COMP005 (June 2025) and COMP006 (February 2026), both hitting primary endpoints with high statistical significance. According to FDA trackers, Compass targets a rolling New Drug Application (NDA) submission in Q4 2026, with a potential FDA approval decision by late 2026 or early 2027. COMP360 retains its Breakthrough Therapy Designation, which provides intensive FDA guidance and rolling review eligibility.
Usona Institute (psilocybin, major depressive disorder): Usona, a Wisconsin-based nonprofit, confirmed its receipt of a National Priority Voucher and stated the designation accelerates FDA review to approximately one to two months after NDA submission. World Today Journal reports Usona's indication — major depressive disorder rather than treatment-resistant depression — covers a far larger patient population, though its Phase 3 results have not yet been publicly announced.
Transcend Therapeutics (methylone, PTSD): Transcend's TSND-201 is a synthetic compound similar to MDMA but with a distinct chemical profile designed to address the regulatory and ethical concerns that led to the FDA's August 2024 rejection of Lykos Therapeutics' MDMA application. Transcend is expected to be acquired by Otsuka Pharmaceutical in Q2 2026.
| Compound | Company | Indication | Stage | Priority Voucher |
| Psilocybin (COMP360) | Compass Pathways | Treatment-resistant depression | Two positive Phase 3 trials; NDA submission Q4 2026 | Yes (April 24, 2026) |
| Psilocybin | Usona Institute | Major depressive disorder | Phase 3 (results pending) | Yes (April 24, 2026) |
| Methylone (TSND-201) | Transcend Therapeutics | PTSD | Phase 3 | Yes (April 24, 2026) |
| FDA approval decision timeline | All three | Various | Late 2026 to early 2027 | 1–2 month review after NDA |
The Executive Order — What It Does and Doesn't Do
President Trump's April 18, 2026 executive order is the strongest federal signal yet that psychedelic therapies are moving from fringe to mainstream. The order directs the Department of Health and Human Services to expedite research, facilitate clinical trial participation, expand Right-to-Try pathways for psychedelics, and prioritize regulatory review of psychedelic drugs for serious mental illness — with particular emphasis on conditions that have not responded to standard treatments.
Critically, however, the executive order does not, by itself, approve any drug or change statutory requirements for FDA approval. "The FDA still requires substantial evidence of safety and efficacy," according to Foley & Lardner's analysis of the order. What the order does is "signal a substantial directional shift in federal policy that is likely to accelerate the pace of psychedelic drug development and may increase investment in the sector."
FDA Commissioner Marty Makary has stated publicly that he expects the agency to issue an approval decision by late summer or fall 2026 for at least one of the priority compounds, and that any approved therapies would be directed for use "in a supervised clinical setting" — a requirement that will shape how these drugs are eventually delivered to patients.
What Treatment-Resistant Depression and PTSD Actually Mean
An estimated 30 to 35% of people with major depressive disorder do not respond to two or more adequately dosed antidepressant trials — a threshold that typically defines "treatment-resistant depression." For these patients, existing options are limited: electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), ketamine infusions, and Spravato (esketamine nasal spray) are approved alternatives, but none work for everyone, and access to specialized facilities is uneven.
PTSD affects approximately 13 million Americans annually, with military veterans, first responders, and survivors of sexual trauma facing the highest rates. Existing FDA-approved medications for PTSD (sertraline and paroxetine) produce complete remission in fewer than 30% of patients. The August 2024 rejection of MDMA-assisted therapy for PTSD — when the advisory committee voted 9-2 against Lykos Therapeutics' application — was a significant setback, driven by concerns about trial-specific design flaws rather than opposition to psychedelic therapy as a category. Transcend's methylone program was specifically designed to address those design concerns.
What the FDA Approval of a Psychedelic Would Actually Mean
If approved, COMP360 would become the first classic psychedelic ever approved by the FDA for a psychiatric indication. Unlike standard antidepressants taken daily, psilocybin therapy in clinical trials has been administered in one to three guided sessions — with therapeutic effects in some studies persisting for weeks to months after a single administration. This delivery model requires a trained therapist or guide present during the session, and it fundamentally differs from the pill-a-day model that has defined psychiatric pharmacology for decades.
The infrastructure challenge for psilocybin therapy is significant. There are currently no FDA-cleared training standards for psilocybin therapy facilitators, no established billing codes for psilocybin therapy sessions under commercial insurance, and no established facility standards. Regulatory approval would trigger a rapid effort to build that infrastructure — with mental health organizations, health systems, payers, and regulators all needing to move quickly.
Frequently Asked Questions
What did the FDA do with psychedelic drug applications in April 2026?
On April 24, 2026, the FDA issued National Priority Vouchers to three companies: Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). These vouchers compress FDA review from 10–12 months to 1–2 months after application submission.
Is psilocybin approved by the FDA?
Not yet. As of June 2026, psilocybin remains a Schedule I controlled substance federally. Compass Pathways is targeting a rolling NDA submission in Q4 2026, and FDA Commissioner Makary has indicated a decision could come by late summer or fall 2026. FDA approval is not guaranteed and still requires the full legal evidentiary standard.
What is the difference between treatment-resistant depression and regular depression?
Treatment-resistant depression is typically defined as major depressive disorder that has not responded to at least two adequately dosed antidepressant trials. It affects an estimated 30–35% of people with depression. This population has the fewest effective treatment options and the highest disease burden.
Will psilocybin be available in pill form at pharmacies?
No. Clinical trials have used psilocybin in one to three guided sessions administered in a clinical setting with a trained therapist or facilitator present. Any approved version would require a supervised setting — not a daily prescription. The delivery infrastructure for this model does not yet fully exist and would need to be built following FDA approval.
Why was MDMA for PTSD rejected, and is this different?
The FDA's advisory committee voted 9-2 against Lykos Therapeutics' MDMA therapy for PTSD in August 2024, citing trial design concerns including selection bias, functional unblinding, and ethical violations at one trial site. Transcend Therapeutics' methylone compound was deliberately designed to address those specific deficiencies and is a different molecule (methylone vs. MDMA) with an independently designed clinical trial.
